PuSH - Publication Server of Helmholtz Zentrum München

Neudorfer, J.* ; Schmidt, B.* ; Huster, K.M. ; Anderl, F.* ; Schiemann, M. ; Holzapfel, G.* ; Schmidt, T.* ; Germeroth, L.* ; Wagner, H.* ; Peschel, C.* ; Busch, D.H. ; Bernhard, H.

Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens.

J. Immunol. Methods 320, 119-131 (2007)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
The development of MHC/peptide multimers has facilitated the visualization and purification of antigen-specific T cells. However, the persistence of multimers leads to prolonged T cell receptor signaling and subsequently to altered T-cell function. We have recently developed a new type of MHC/peptide multimers, which can be dissociated from the T cell. Herein, we have generated and tested for the first time reversible HLA/peptide multimers, termed Streptamers, for the isolation of human T cells. The Streptamer technique demonstrates the specificity and sensitivity of conventional HLA/peptide tetramers with regards to the sorting of human T lymphocytes. This is shown for T cells directed against immunogenic peptides derived from viral and tumor-associated antigens. We show that antigen-specific cytotoxic T cells remain functionally active following Streptamer dissociation, whereas lytic function and proliferation of the T cells is impaired in the presence of conventional tetramers. These novel HLA/peptide Streptamer reagents allow the isolation of antigen-specific T cells with preserved function and, therefore, facilitate the development of adoptive T cell transfer regimens for the treatment of patients with cancer or infectious diseases.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
ISSN (print) / ISBN 0022-1759
e-ISSN 1872-7905
Journal Journal of Immunological Methods
Quellenangaben Volume: 320, Issue: 1-2, Pages: 119-131 Article Number: , Supplement: ,
Publisher Elsevier
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) CCG Antigen-specific Immunotherapy (VIRO-KVA)